---
source: https://investor.illumina.com/news/press-release-details/2025/Illumina-to-acquire-SomaLogic-accelerating-its-proteomics-business-and-advancing-the-companys-multiomics-strategy/default.aspx
date: 2025-09-10
type: Company
---

# Illumina to Acquire SomaLogic for $425M

Illumina entered definitive agreement to acquire SomaLogic from Standard BioTools, advancing its multiomics strategy.

## Transaction Details

- **Price:** $350M cash at closing + up to $75M in performance-based milestones + royalties
- **Seller:** Standard BioTools (acquired SomaLogic January 2024)
- **Expected Close:** H1 2026
- **Profitability:** Expected 2027 (non-GAAP operating income)
- **Margin Parity:** Expected 2028 (in line with Illumina)

## About SomaLogic

- **Employees:** ~250 worldwide
- **Headquarters:** Boulder, Colorado (lab, office, manufacturing)
- **Technology:** SOMAmer reagents
- **Capability:** Up to 9,500 unique human protein targets per experiment
- **Platform:** SomaScanÂ® Proteomics Assay on NovaSeq hardware

## Strategic Rationale

"The acquisition of SomaLogic will enhance Illumina's presence in the expanding proteomics market and advance the multiomics strategy we announced in 2024. This will strengthen the value of the NovaSeq X product today and unlock greater capabilities in the future." - Jacob Thaysen, CEO

## Background

Builds on December 2021 co-development agreement to bring SomaScan Assay onto Illumina's high-throughput NGS platforms.

## Illumina Protein Prep

- Currently with ~40 early-access customers
- General availability: Q3 2025
- Measures up to 9,500 unique human protein targets in single experiment
